Compare FRST & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | STRO |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.4M | 524.8M |
| IPO Year | 2006 | N/A |
| Metric | FRST | STRO |
|---|---|---|
| Price | $14.35 | $26.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 241.2K | ★ 255.3K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 477.27 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.63 | N/A |
| P/E Ratio | $47.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.25 | $0.67 |
| 52 Week High | $14.97 | $43.85 |
| Indicator | FRST | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 30.61 |
| Support Level | $13.71 | $23.43 |
| Resistance Level | $14.45 | $27.96 |
| Average True Range (ATR) | 0.28 | 3.47 |
| MACD | -0.03 | -1.79 |
| Stochastic Oscillator | 53.70 | 0.40 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. The company has two reportable segments: Primis Bank. This segment specializes in providing financing services to businesses in various industries along with consumer and residential loans to individuals. Primis Mortgage. This segment specializes in originating mortgages in a majority of the U.S. The revenue is from Primis Bank.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.